Player FM - Internet Radio Done Right
Checked 10d ago
Lisätty nine vuotta sitten
Indhold leveret af The Immune-Mediated Inflammatory Disease Forum. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Immune-Mediated Inflammatory Disease Forum eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
Podcasts der er værd at lytte til
SPONSORERET
<
<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/the-unshakeables">The Unshakeables</a></span>
The Unshakeables podcast from Chase for Business and iHeartMedia's Ruby Studio dives into the unbelievable “What are we gonna do now?” moments that changed everything for small business owners. From mom-and-pop coffee shops to auto-detailing garages, every small business owner knows that the journey is full of the unexpected. A single make-or-break experience can change the course of your business forever. Those who stand firm in their resolve have a special name. We call them The Unshakeables. These are their stories. Join Ben Walter, CEO of Chase for Business, and a lineup of special co-hosts as they speak with small business owners across America who’ve gone through some of the most unexpected situations anyone can face and walked away stronger for it. These aren’t stories about the darlings of Silicon Valley or titans of Wall Street. These are real stories from real people behind the small companies powering their communities every day. The speakers’ opinions belong to them and may differ from opinions of J.P. Morgan Chase & Co and its affiliates. Views presented on this podcast are those of the speakers; they are as of the podcast release date and they may not materialize.
The IMID Forum
Marker alle som (u)afspillede ...
Manage series 1044916
Indhold leveret af The Immune-Mediated Inflammatory Disease Forum. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Immune-Mediated Inflammatory Disease Forum eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
…
continue reading
338 episoder
Marker alle som (u)afspillede ...
Manage series 1044916
Indhold leveret af The Immune-Mediated Inflammatory Disease Forum. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Immune-Mediated Inflammatory Disease Forum eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
…
continue reading
338 episoder
Kaikki jaksot
×T
The IMID Forum
1 Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR T-cell therapy 11:18
11:18
Afspil senere
Afspil senere
Lister
Like
Liked
11:18Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, Professor McInnes discusses two papers: subgroups of patients with early RA with or without bDMARD who reached sustained DMARD-free remission and barriers to the widespread adoption of CAR T-cell therapy in rheumatic diseases.…
T
The IMID Forum
1 Discussing AxSpA Podcast: Efficacy and Safety of Upadacitinib 18:42
18:42
Afspil senere
Afspil senere
Lister
Like
Liked
18:42Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.…
T
The IMID Forum
1 Discussing RA: Insights into Filgotinib and Tofacitinib in RA 24:13
24:13
Afspil senere
Afspil senere
Lister
Like
Liked
24:13Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.…
T
The IMID Forum
ACR 2024 Review Podcast by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
1 PsA Podcast: DISCOVER-2 and BE OPTIMAL/BE COMPLETE post-hoc analyses 30:53
30:53
Afspil senere
Afspil senere
Lister
Like
Liked
30:53Join Professors Peter Nash and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a post hoc analysis examining the rapid and sustained efficacy of bimekizumab in PsA patients across different subgroups, focusing on improvements in pain, fatigue, and physical function over 16 weeks. The conversation also covered a long-term analysis of guselkumab assessing the durability of clinical improvements in joint and skin symptoms in PsA patients over a 2-year period.…
T
The IMID Forum
1 Discussing RA: Insights into Filgotinib and Tofacitinib in RA 19:16
19:16
Afspil senere
Afspil senere
Lister
Like
Liked
19:16Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.…
T
The IMID Forum
1 Webinar Highlights Podcast: CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases 26:39
26:39
Afspil senere
Afspil senere
Lister
Like
Liked
26:39Webinar Highlights Podcast: Join Professor Iain McInnes and Professor Georg Schett as they discuss the recent webinar hosted on the IMID Forum: “CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases”. Listen to them discuss key highlights from the webinar including the development of CAR T-cell therapy, the application of CAR T to autoimmune diseases, and the potential risks and reservations associated with this therapeutic approach.…
T
The IMID Forum
ACR 2024 Highlights: Day 3 by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
ACR 2024 Highlights: Day 2 by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
ACR 2024 Highlights: Day 1 by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
ACR 2024: Preview Podcast by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
1 AxSpA Podcast: Efficacy and Safety of IV secukinumab 23:30
23:30
Afspil senere
Afspil senere
Lister
Like
Liked
23:30Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.
T
The IMID Forum
1 Discussing RA: Navigating JAKis, TNFis, and the quest for optimal RA therapy 22:03
22:03
Afspil senere
Afspil senere
Lister
Like
Liked
22:03Join Professor Iain McInnes and Professor Leonard Calabrese for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the efficacy and safety of JAK inhibitors and TNF inhibitors for rheumatoid arthritis, while also uncovering the best treatment strategies for difficult-to-treat RA.…
T
The IMID Forum
1 Author Interview: Derin Karacabeyli, 2024 33:27
33:27
Afspil senere
Afspil senere
Lister
Like
Liked
33:27Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Derin Karacabeyli of Arthritis Research Canada, a rheumatologist and resident in the University of British Columbia Clinician Investigator Program, as they discuss his recent paper ‘Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study’, published in PLoS One on 08th August 2024.…
T
The IMID Forum
1 Webinar Highlights Podcast 2: Evolving Therapeutic Strategies for Psoriatic Diseases 32:56
32:56
Afspil senere
Afspil senere
Lister
Like
Liked
32:56Webinar Highlights Podcast: Join Professor Christopher Ritchlin, and Professor Philip Mease as they discuss the recent webinar hosted on the IMID Forum ‘Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2’. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the similarities and differences in pathology in skin and joints across psoriatic arthritis, and a special focus on IL-23, and its clinical data and impact across different tissue domains.…
T
The IMID Forum
1 PsA Podcast: Bimekizumab: Efficacy, safety, and effectiveness in PsA 21:04
21:04
Afspil senere
Afspil senere
Lister
Like
Liked
21:04Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a matching-adjusted indirect comparison (MAIC) to assess the comparative efficacy of bimekizumab and risankizumab in patients with psoriatic arthritis over 52 weeks, and a post hoc analysis investigating the efficacy and safety of bimekizumab in PsA patients with or without concomitant methotrexate over 52 weeks.…
T
The IMID Forum
1 Discussing RA: Long-term safety and efficacy of upadacitinib in SELECT trials 19:24
19:24
Afspil senere
Afspil senere
Lister
Like
Liked
19:24Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.…
T
The IMID Forum
1 Discussing AxSpA: Incidence of uveitis following bimekizumab treatment 24:11
24:11
Afspil senere
Afspil senere
Lister
Like
Liked
24:11Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.…
T
The IMID Forum
1 Author Interview: Professor Laura Andreoli, 2024 44:09
44:09
Afspil senere
Afspil senere
Lister
Like
Liked
44:09Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.…
T
The IMID Forum
1 Discussing RA: Neutrophil-to-lymphocyte ratio and treatment response to filgotinib 16:05
16:05
Afspil senere
Afspil senere
Lister
Like
Liked
16:05Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment response to filgotinib.…
T
The IMID Forum
1 Discussing PsA: Guselkumab and analysis of genetic markers 25:46
25:46
Afspil senere
Afspil senere
Lister
Like
Liked
25:46Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered the post hoc analysis of PsA patients receiving guselkumab, focusing on disease control across domains and patient characteristics, and a systematic review and meta-analysis on genetic markers and their response to biologics in inflammatory diseases.…
T
The IMID Forum
1 Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status 22:14
22:14
Afspil senere
Afspil senere
Lister
Like
Liked
22:14Join us for the latest axSpA podcast brought to you by the Immune- ediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the results of a Phase 3 trial on upadacitinib in nr-axSpA and the clinical outcomes of certolizumab pegol treatment in nr-axSpA stratified by baseline MRI and CRP status.…
T
The IMID Forum
1 Discussing PsA: Bimekizumab therapy in PsA 29:49
29:49
Afspil senere
Afspil senere
Lister
Like
Liked
29:49Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the latest publication by Su, et al. and discuss the latest in bimekizumab therapy in PsA.
T
The IMID Forum
1 IMID Author Interview: Dr Blanca Hernández-Cruz, 2024 33:50
33:50
Afspil senere
Afspil senere
Lister
Like
Liked
33:50Join Professor Peter Nash from the Griffith University in Brisbane, and Blanca Hernández-Cruz, a rheumatologist at Virgen Macarena University Hospital in Seville, as they discuss her recent paper ‘Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry’.…
T
The IMID Forum
1 Discussing AxSpA: Long-term etanercept response & real-world effectiveness of tofacitinib & adalimumab 29:48
29:48
Afspil senere
Afspil senere
Lister
Like
Liked
29:48Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-world clinical context.…
T
The IMID Forum
1 Discussing PsA: 2023 EULAR recommendations and improvements in PROs with deucravacitinib 28:33
28:33
Afspil senere
Afspil senere
Lister
Like
Liked
28:33Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the updated 2023 EULAR recommendations for PsA and the improvement of PROs reported in a Phase 2 trial with deucravacitinib.
T
The IMID Forum
1 Discussing AxSpA: Secukinumab retention over time & sacroiliac joint improvements between DMARDs 33:01
33:01
Afspil senere
Afspil senere
Lister
Like
Liked
33:01Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvements is sacroiliac joint symptoms across patients with AS and axSpA treated with different DMARDs.…
T
The IMID Forum
1 Discussing PsA: Long-term safety of ixekizumab & bimekizumab treatment in a TNFi-IR population 38:13
38:13
Afspil senere
Afspil senere
Lister
Like
Liked
38:13Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the long-term safety of ixekizumab as well as bimekizumab treatment in a TNFi-IR population.
T
The IMID Forum
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that that add to the knowledge of common treatments relating to RA. In our first paper, Juergen Rech and colleagues present the results of the ARIAA study, which shows that abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. Our second paper is from Juergen Rech and colleagues, where they present the results of the ARIAA study which investigated whether abatacept inhibits inflammation symptoms and progression to RA in high-risk patients. To access detailed summary slides for the papers discussed today, visit imidforum.com.…
T
The IMID Forum
1 Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment 32:38
32:38
Afspil senere
Afspil senere
Lister
Like
Liked
32:38Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs) and 24-month retention rates between patients with axSpA and PsA that were treated with secukinumab.…
T
The IMID Forum
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that show the long-term safety and efficacy of JAK inhibitors, both of which have a study period of 6.5 years. In our first paper, Roberto Caporali and colleagues show long-term safety and efficacy data for baricitinib as an RA therapy. Our second paper is from Christina Charles-Schoeman and her colleagues, where they present long-term data on the effect of upadacitinib on laboratory parameters in people with RA. To access detailed summary slides for the papers discussed today, visit imidforum.com.…
T
The IMID Forum
1 Discussing PsA: Clinical Response to Guselkumab & Sequential Lines of b/tsDMARDs 32:10
32:10
Afspil senere
Afspil senere
Lister
Like
Liked
32:10Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, including the clinical response to guselkumab and the research surrounding sequential lines of b/tsDMARDs.
T
The IMID Forum
Join Professor Iain McInnes for the first episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that aimed to advise on treatment of rheumatic diseases in a real-world setting. In our first paper, Emma Dures and her colleagues compiled the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Our second paper is from Kehinde Sunmboye and his colleagues, where they investigated the incidence of MACE in a multi-ethnic population that were treated with JAK inhibitors. To access detailed summary slides for the papers discussed today, visit imidforum.com.…
T
The IMID Forum
1 Discussing AxSpA: Long-Term Outcomes of Secukinumab & JAKis in Clinical Practice 25:05
25:05
Afspil senere
Afspil senere
Lister
Like
Liked
25:05Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the long-term impact of secukinumab treatment on bone-related outcomes and BTMs in r-AxSpA patients over two years. Our faculty then move on to discuss another publication, which presents JAKi treatment recommendations for IMIDs from a two-round modified RAM study with 21 subject matter experts.…
T
The IMID Forum
1 Discussing PsA: Secukinumab & The Effect of Sex on the Long-Term Persistence of Targeted Therapies 30:33
30:33
Afspil senere
Afspil senere
Lister
Like
Liked
30:33Join Professors Peter Nash, Philip Mease, Frank Behrens, and Laura Coates as they discuss the top publications in the world of PsA. They discuss two highly relevant topics in the field, namely the effect of sex on the long-term persistence of targeted therapies, as well as the impact of secukinumab on synovitis and enthesitis.…
T
The IMID Forum
1 Discussing AxSpA: Bimekizumab in AxSpA & Secukinumab Patient Clustering 26:26
26:26
Afspil senere
Afspil senere
Lister
Like
Liked
26:26Join us for the latest axSpA podcast brought to you by the CSF! This month Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Leiden University Medical Centre and Zuyderland Medical Centre, is joined once again by experts with a wealth of clinical knowledge. Joining her is Hideto Kameda, Professor of Internal Medicine at Toho University as well as Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA. Also joining this insightful group is Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and Medical Director of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, Germany In the first paper discussed, the authors compared the efficacy and safety of bimekizumab with biologic/targeted synthetic disease-modifying antirheumatic drugs in nr-axSpA and AS. Our second paper then goes on to identify distinct clinical clusters based on patient demographics and baseline clinical indicators from the clinical development programme of secukinumab in patients with a variety of rheumatological conditions.…
T
The IMID Forum
1 Author Interview: Dr Adam Goldman, 2024 21:07
21:07
Afspil senere
Afspil senere
Lister
Like
Liked
21:07Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Adam Goldman, an epidemiology researcher at The Chaim Sheba Medical Center in Tel-Hashomer, and an epidemiology researcher and lecturer at Tel-Aviv University, as they discuss his recent paper ‘Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports’, published in Seminars in Arthritis and Rheumatism on 17th May 2024.…
T
The IMID Forum
1 Author Interview: Professor Daniel Blockmans, 2024 26:44
26:44
Afspil senere
Afspil senere
Lister
Like
Liked
26:44Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Daniel Blockmans, from the Department of Internal Medicine at the University Hospitals Leuven, as they discuss his recent paper ‘Efficacy and safety of upadacitinib in patients with giant cell arteritis (SELECT-GCA): A double-blind, randomized controlled Phase 3 trial’, published in Annals of the Rheumatic Diseases on June 2024.…
T
The IMID Forum
Join Professor Iain McInnes and guest Professor Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, two papers that cover important topics in rheumatology are highlighted: the first paper presents the 5-year efficacy and safety results of upadacitinib in RA, while the second provides an overview of the literature and guidance on discussing outcomes regarding children born of mothers with autoimmune rheumatic diseases.…
T
The IMID Forum
Join Professors Iain McInnes, Peter Nash, and Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode they discuss two papers, one that investigated the long-term safety of filgotinib in moderate-to-severe RA, and the other a postmarketing analysis of adverse cardiovascular events with JAKi treatments in RA.…
T
The IMID Forum
Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they review their top sessions in RA, PsA, and axSpA from EULAR 2024, providing insight into how these data will shape clinical practice going forward.
T
The IMID Forum
Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Saturday, June 15).
T
The IMID Forum
Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of EULAR 2024 (Friday, June 14).
T
The IMID Forum
Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of EULAR 2024 (Thursday, June 13).
T
The IMID Forum
Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Wednesday, June 12).
T
The IMID Forum
Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they guide you through their top selections in RA, PsA, and axSpA at EULAR 2024, so that you can better plan your time at what will be a busy and exciting congress.
T
The IMID Forum
Join Professor Iain McInnes and guests Professor Janet Pope and Dr Sofia Ramiro for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers that investigated the long-term safety of JAK inhibitors from Phase 3 trials. In our first paper, Maya Buch and colleagues examined extended MACE endpoints with tofacitinib versus TNFi. Our second paper is from Gerd Burmester and colleagues present long-term efficacy and safety data for upadacitinib through five years. To access detailed summary slides for the papers discussed today, visit imidforum.com.…
T
The IMID Forum
1 IMID Author Interview: Dorthe Berthelsen, 2024 23:26
23:26
Afspil senere
Afspil senere
Lister
Like
Liked
23:26Join Professor Peter Nash from the Griffith University in Brisbane, and Dorthe Berthelsen, a PhD student and physiotherapist at the Parker Institute in Copenhagen and at the University of Southern Denmark, as they discuss her recent paper ‘“I couldn't carry on taking a drug like that”: A qualitative study of patient perspectives on side effects from rheumatology drugs.’…
T
The IMID Forum
1 Webinar Highlights Podcast: Evolving Therapeutic Strategies for Psoriatic Diseases 29:42
29:42
Afspil senere
Afspil senere
Lister
Like
Liked
29:42Webinar Highlights Podcast: Join Professor Iain McInnes and Associate Professor Laura Coates on the Immune-Mediated Inflammatory Disease Forum in their discussion on the recent webinar “Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar”. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the pathophysiology of IL-23 inhibitors compared with TNF and IL-17 inhibitor therapies, and the relationship between IL-23 inhibitor MOA variation and real-world patient data.…
T
The IMID Forum
1 IMID Author Interview: Dr Jake Weddell, 2024 21:01
21:01
Afspil senere
Afspil senere
Lister
Like
Liked
21:01Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jake Weddell, an academic rheumatology trainee at Leeds Teaching Hospitals NHS Trust, as they discuss his recent paper ‘Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis.’…
T
The IMID Forum
1 IMID Author Interview: Professor Frank Verhoeven, 2024 20:36
20:36
Afspil senere
Afspil senere
Lister
Like
Liked
20:36Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Frank Verhoeven, an Assistant Professor in Rheumatology at the CHU Besancon in France, as they discuss his recent paper ‘Effects of disease‑modifying anti‑rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: A systematic review and meta‑analysis.’…
T
The IMID Forum
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers related to the long-term safety of JAK inhibitors compared to TNF inhibitors. In our first paper, Christina Charles-Schoeman and colleagues assessed the risk of venous thromboembolism in patients with RA initiating tofacitinib or TNFi. Our second paper is from Roy Fleischmann and colleagues compare the long-term efficacy and safety data of upadacitinib switched from adalimumab and in adalimumab switched from upadacitinib. To access detailed summary slides for the papers discussed today, visit imidforum.com.…
T
The IMID Forum
1 Author Interview: Professor Maria Antonietta D’Agostino, 2024 22:15
22:15
Afspil senere
Afspil senere
Lister
Like
Liked
22:15Join Professor Peter Nash from the Griffith University in Brisbane, and Maria Antonietta D’Agostino, the Head of the Rheumatology Department at the Catholic University of the Sacred Heart in Rome, as they discuss her recent paper 'Effects of Secukinumab on Synovitis and Enthesitis in Patients with Psoriatic Arthritis: 52-week Clinical and Ultrasound Results from the Randomised, Double-blind ULTIMATE Trial with Open Label Extension'.…
T
The IMID Forum
1 Author Interview: Professor Dennis McGonagle, 2024 31:18
31:18
Afspil senere
Afspil senere
Lister
Like
Liked
31:18Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Dennis McGonagle, a Clinical Professor at the University of Leeds School of Medicine, as they discuss his recent paper ‘Association of the Clinical Components in the Distal Interphalangeal Joint Synovio-entheseal Complex and Subsequent Response to Ixekizumab or Adalimumab in Psoriatic Arthritis.’…
T
The IMID Forum
1 Author Interview: Dr Jürgen Rech, 2024 32:30
32:30
Afspil senere
Afspil senere
Lister
Like
Liked
32:30Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jürgen Rech, a Senior Physician at the Friedrich-Alexander University of Erlangen-Nürnberg, as they discuss his recent paper ‘Abatacept Inhibits Inflammation and Onset of Rheumatoid Arthritis in Individuals at High Risk (ARIAA): A Randomised, International, Multicentre, Double-blind, Placebo-controlled Trial.’…
T
The IMID Forum
1 Author Interview: Dr Mahta Mortezavi, 2024 20:18
20:18
Afspil senere
Afspil senere
Lister
Like
Liked
20:18Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Mahta Mortezavi, a Clinical Director for Drug Discovery and Early Development as part of the Anti-infectives Research Unit at Pfizer, as they discuss her recent paper ‘Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumour necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.’…
T
The IMID Forum
1 Author Interview: Professor Andrew Cope, Professor Paul Emery and Professor John Issacs 43:10
43:10
Afspil senere
Afspil senere
Lister
Like
Liked
43:10Join Professor Peter Nash from the Griffith University in Brisbane, as well as Professors Andrew Cope, Professor of Rheumatology and Head of the Centre for Rheumatic Diseases at Kings College London, Professor Paul Emery, Clinical Professor and Director of the Leeds Biomedical Research Centre, and Professor John Isaacs, Professor of clinical immunology and Director of Newcastle Biomedicine Versus Arthritis Experimental Arthritis Treatment Centre. Together they discuss the recent paper ‘Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial’, published in The Lancet on 13th February 2024.…
T
The IMID Forum
1 Author Interview: Dr Kehinde Sunmboye, 2024 18:05
18:05
Afspil senere
Afspil senere
Lister
Like
Liked
18:05Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Kehinde Sunmboye, a consultant rheumatologist at the University Hospitals of Leicester NHS Trust, in this episode of the Author Interview series. Dr Sunmboye discusses his recent paper 'Cardiovascular safety of Janus Kinase inhibitor therapy in a multi-ethnic population' with Professor Nash in this exclusive interview.…
T
The IMID Forum
1 Author Interview: Professor Andrea Rubbert-Roth, 2023 25:17
25:17
Afspil senere
Afspil senere
Lister
Like
Liked
25:17Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrea Rubbert-Roth, a doctor of rheumatology and internal medicine at the Kantonsspital St Gallen in Switzerland, as they discuss her recent paper 'Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis'.…
T
The IMID Forum
1 Discussing Rheumatology: December 2023 10:37
10:37
Afspil senere
Afspil senere
Lister
Like
Liked
10:37Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that compare the efficacy and safety of JAK inhibitors as RA therapies. In our first paper, Shinya Hayashi and his colleagues carried out a retrospective study to compare the efficacy of JAK inhibitors in treating RA. For our second paper, Christina Charles-Schoeman and her colleagues compared the incidence of MACE and VTE in RA and PsA patients treated with upadacitinib, adalimumab and MTX.…
T
The IMID Forum
1 CSF Author Interview: Professor Martin Bergman, 2023 27:25
27:25
Afspil senere
Afspil senere
Lister
Like
Liked
27:25Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Martin Bergman, a Clinical Associate Professor of Medicine at the Drexel University College of Medicine in Philadelphia, to discuss his recent paper ‘One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.’ Detailed summary slides of this paper and many more publications, are free to view and download in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Upadacitinib treating bDMARD-IR PsA & Post-marketing surveillance of tofacitinib treating PsA & RA 31:28
31:28
Afspil senere
Afspil senere
Lister
Like
Liked
31:28Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, is joined by Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre as well as Doctor Frank Behrens, Medical director at Goethe-University. The papers covered in this topical discussion highlight two interesting areas of the modern PsA therapeutic landscape. The first of the publications discusses the safety and efficacy of upadacitinib in the treatment of patients with PsA and an inadequate response to bDMARDs through a three-year study. The second, explores an analysis of the real-world safety profile of tofacitinib in the treatment of patients with PsA. If you would like to read more about the topics discussed, head over to cytokinesignalling.com, where you’ll find detailed summary slides of each of the papers.…
T
The IMID Forum
1 AxSpA Podcast: The Efficacy and Safety of Ixekizumab & Tildrakizumab 25:40
25:40
Afspil senere
Afspil senere
Lister
Like
Liked
25:40Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands, is joined by Professor Hideto Kameda, Professor of Internal Medicine at Toho University and Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA to discuss the Efficacy and Safety of Ixekizumab & Tildrakizumab. In the first paper discussed, it describes the safety and efficacy of ixekizumab treatment in patients with r-axSpA and nr-axSpA for up to 156 weeks. The second study discussed goes on to assess the safety and efficacy of tildrakizumab in patients with active AS.…
T
The IMID Forum
1 Discussing Rheumatology: September 2023 11:13
11:13
Afspil senere
Afspil senere
Lister
Like
Liked
11:13Join Prof Iain McInnes as he reviews two interesting papers , that retrospectively investigate the properties of JAK inhibitors. In our first paper, Peter Taylor and his colleagues review the pharmacological differences between JAK inhibitors, and how these may affect safety and efficacy. In the second, Qige Wei and colleagues carried out a network meta-analysis of 14 RCTS to identify any associations between RA therapies and MACE or all-cause mortality. To access detailed summary slides of the papers discussed, visit cytokinesignalling.com.…
T
The IMID Forum
Professor Peter Nash from the Griffith University in Brisbane, is joined by Doctor Sofia Ramiro, a Consultant Rheumatologist and Senior Researcher at Leiden University Medical Centre to discuss her recent paper 'Do Fatty Lesions Explain the Effect of Inflammation on New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis? Results From the SIAS Cohort and ASSERT Trial'…
T
The IMID Forum
Join Prof Iain McInnes as he reviews two interesting papers. Our first paper today by Charles-Schoeman and colleagues compared paraoxonase activity in RA patients treated with tofacitinib, with a focus of PON1 genotypes. Furthermore, the relationship between PON1 genotypes and the risk of MACE and malignancy were also investigated. In our second paper, Peter Taylor and colleagues evaluated the results of several baricitinib RCTs and real-world evidence studies.…
T
The IMID Forum
1 AxSpA Podcast: Tofacitinib, Golimumab, and Fatigue 19:21
19:21
Afspil senere
Afspil senere
Lister
Like
Liked
19:21Join Professor Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to use mediation modelling to determine whether tofacitinib improved fatigue symptoms directly or indirectly. Our second paper shows that IV-golimumab reduces fatigue symptoms in patients with ankylosing spondylitis.…
T
The IMID Forum
Join Prof Iain McInnes as he reviews two interesting papers. Our first paper today by Roy Fleischmann and his colleagues compares the incidence of serious adverse events in RA patients with a higher risk of cardiovascular events and the overall RA population in a post-hoc study. They also compared the incidence rate of adverse events for upadacitinib, adalimumab and methotrexate, or methotrexate monotherapy. In our second paper, Mohammed Khan and colleagues compared tofacitinib against methotrexate as first-line therapies against RA, with a focus on treatment remission.…
T
The IMID Forum
1 PsA Podcast: Secukinumab in Oligoarticular PsA & JAK Inhibition-related Malignancies 32:46
32:46
Afspil senere
Afspil senere
Lister
Like
Liked
32:46Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre and Doctor Frank Behrens, Medical director at Goethe-University, as they discuss two interesting areas of the modern PsA therapeutic landscape. The first of the publications discussed pertains to the use of secukinumab in oligoarticular PsA. We will then go on to expand upon the latest in the evolving story begun by ORAL Surveillance, as we discuss the latest meta-analysis of the relationship between JAK inhibition and malignancies.…
T
The IMID Forum
Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Laura Coates a NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, discussing her recent paper 'Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study'.…
T
The IMID Forum
Professor Peter Nash from the Griffith University in Brisbane, is joined by Dr Mark Russell, a clinical research fellow at the Centre for Rheumatic Diseases, King’s College London to discuss his recent paper 'JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications'.
T
The IMID Forum
Join Prof Iain McInnes as he reviews two interesting papers surrounding filgotinib and baricitinib. Our first paper today by Walter Reinisch and his colleagues highlight the latest update from the Phase 2 MANTA and MANTA-Ray studies, exploring the impact of filgotinib semen parameters and sex hormones in men with inflammatory diseases. In the second paper, David Simon and his team investigate the impact of baricitinib on volumetric bone mineral density and several other markers of bone health in RA patients.…
T
The IMID Forum
1 AxSpA Podcast: Secukinumab Optimisation & Ixekizumab Treatment for PAEs 22:00
22:00
Afspil senere
Afspil senere
Lister
Like
Liked
22:00Join Professors Atul Deodhar, Xenofon Baraliakos, Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to determine when the optimal time to start secukinumab treatment is demonstrated by a significant difference between baseline and post treatment BASDAI scores. Our second paper the goes on to evaluate a case report of a 45-year-old male, with AS, and adalimumab-induced refractory paradoxical palmoplantar pustulosis, after failure of prior secukinumab treatment.…
T
The IMID Forum
Join Professor Peter Nash as he goes through our top abstracts, posters, and presentations from Day 4 of EULAR 2023 today (Saturday 3 June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
T
The IMID Forum
Join Professor Lorenzo Dagna as she goes through our top abstracts, posters, and presentations from Day 3 of EULAR 2023 today (Friday 2 June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
T
The IMID Forum
1 PsA Podcast: Impact of Biological Sex on Advanced Therapies & Upadacitinib-related Malignancies 27:19
27:19
Afspil senere
Afspil senere
Lister
Like
Liked
27:19Join Philip Mease, Professor at the University of Washington School of Medicine and Director of Rheumatology Research at the Swedish Medical Centre in Seattle, USA, and Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, as they discuss two important topics from the world of contemporary PsA treatment. The first of the publications they will be reviewing sought to compare patient characteristics and efficacy and safety of advanced therapies between male and female patients with PsA participating in RCTs. They then go on to discuss a second publication describing malignancies in patients with a variety of rheumatic conditions treated with upadacitinib or active comparators.…
T
The IMID Forum
1 AxSpA Podcast: Safety and Efficacy of Tofacitinib and Bimekizumab 33:10
33:10
Afspil senere
Afspil senere
Lister
Like
Liked
33:10Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.…
T
The IMID Forum
1 AxSpA Podcast: Safety and Efficacy of Tofacitinib and Bimekizumab 33:10
33:10
Afspil senere
Afspil senere
Lister
Like
Liked
33:10Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.…
T
The IMID Forum
1 PsA Podcast: Gender differences in treating PsA & safety of guselkumab in treating PsO and PsA 21:09
21:09
Afspil senere
Afspil senere
Lister
Like
Liked
21:09Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, Philip Mease, Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Centre in Seattle, USA, as well as Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre as they discuss two intriguing aspects of the contemporary PsA treatment landscape. The first of the publications relates to the effects of gender on disease characteristics, treatment impact and treatment persistence. The second publication explores the long-term safety profile of guselkumab in the treatment of PsO and PsA.…
T
The IMID Forum
1 Discussing Rheumatology: November 2023 10:11
10:11
Afspil senere
Afspil senere
Lister
Like
Liked
10:11Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that look at the incidence of disease. The first paper, the GBD 2021 Other Musculoskeletal Disorders Collaborators systematically analysed the global burden of musculoskeletal disorders, and used these data to predict prevalence up to 2050 and the second paper, Yvette Meissner and her colleagues used the German RABBIT registry to investigate the relationship between MACE risk and JAK inhibitors, TNF inhibitors, and DMARDs. To access detailed summary slides for the papers discussed today, visit cytokinesignalling.com.…
T
The IMID Forum
Join Sofia Ramiro as she goes through our top abstracts, posters, and presentations from Day 4 of ACR 2023 today (Wednesday 15 November). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
T
The IMID Forum
Join Grace Wright as she goes through our top abstracts, posters, and presentations from Day 3 of ACR 2023 today (Tuesday 14 November). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
T
The IMID Forum
Join Laura Coates as she goes through our top abstracts, posters, and presentations from Day 2 of ACR 2023 today (Monday 13 November). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
T
The IMID Forum
Join Iain McInnes as he goes through our top abstracts, posters, and presentations from Day 1 of ACR 2023 today (Sunday 12 November). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
T
The IMID Forum
Join Dr Sofia Ramiro as she previews our highlights this ACR, introducing some of the top abstracts and posters we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.
T
The IMID Forum
1 Bimekizumab in treating bDMARD-naïve PsA & upadacitinib in treating csDMARD and bDMARD IR PsA 21:21
21:21
Afspil senere
Afspil senere
Lister
Like
Liked
21:21Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia and Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, discussing two intriguing aspects of the contemporary PsA treatment landscape. The first of the publications relates to the safety and efficacy of bimekizumab in bDMARD-naïve patients with PsA through 52 weeks and the second is a publication exploring the real-world safety and efficacy of upadacitinib in patients with PsA and an inadequate response to csDMARDs or bDMARDs.…
T
The IMID Forum
1 axSpA Podcast: Safety and Efficacy of Upadacitinib 26:31
26:31
Afspil senere
Afspil senere
Lister
Like
Liked
26:31Professor Hideto Kameda, Professor of Internal Medicine at Toho University in Japan, is joined by Professor Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and a senior consultant and scientific coordinator of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, Germany, Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands as well as, Atul Deodhar Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA, to discuss the safety and efficacy of Upadacitinib. The first paper evaluated the 52-week safety, tolerability, and efficacy of updacitinib in the SELECT-AXIS 2 study in patients with AS and an inadequate response to bDMARDs and the second paper then goes on to describe, via a narrative review, the safety and efficacy of updacitinib in axSpA…
T
The IMID Forum
1 CSF Author Interview: Dr. David Martin, 2023 39:27
39:27
Afspil senere
Afspil senere
Lister
Like
Liked
39:27Join Professor Peter Nash from the Griffith University in Brisbane, and Dr. David Martin, executive medical director at Pfizer in Massachusetts, USA as they discuss his recent paper 'Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors' Detailed summary slides of this paper and many more publications, are free to view and download in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Discussing Rheumatology: October 2023 11:17
11:17
Afspil senere
Afspil senere
Lister
Like
Liked
11:17Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that look at the epidemiology of autoimmune diseases. The first paper, the GBD 2021 Rheumatoid Arthritis Collaborators systematically reviewed the global RA burden, and used these data to predict prevalence up to 2050 and the second paper, Nathalie Conrad and her colleagues reported the incidence and prevalence of 19 different autoimmune disorders in the United Kingdom, while also stratifying by age, sex, and socioeconomic status. To access detailed summary slides for the papers discussed today, visit cytokinesignalling.com.…
T
The IMID Forum
1 EULAR Recommendations Podcast 2023 with Professor Peter Nash & Dr. Andreas Kerschbaumer 35:13
35:13
Afspil senere
Afspil senere
Lister
Like
Liked
35:13Join Professor Peter Nash from the Griffith University in Brisbane and Dr. Andreas Kerschbaumer of the Division of Rheumatology, Department of Internal Medicine, Medical University of Vienna, Austria, as they discuss an important presentation from this year’s EULAR congress. ‘EULAR Recommendations for the Management of Psoriatic Arthritis: 2023 Update’.…
T
The IMID Forum
Join Dr Sofia Ramiro as she goes through our top abstracts, posters, and presentations from Day 2 of EULAR 2023 today (Thursday 1st June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
T
The IMID Forum
Join Prof Iain McInnes in today’s podcast, where he will be reviewing two papers that investigate treatments for RA patients. In the first paper, Philip Conaghan and colleagues evaluate the effectiveness in a Bruton’s tyrosine kinase inhibitor in treating rheumatoid arthritis in patients with an inadequate response to methotrexate. In the second paper, Vincenzo Venerito and his team assessed the recombinant zoster vaccine in rheumatoid arthritis patients that are treated with JAK inhibitors.…
T
The IMID Forum
Join Professor Xavier Mariette as he goes through our top abstracts, posters, and presentations from Day 1 of EULAR 2023 today (Wednesday 31 May). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
T
The IMID Forum
Join Professor Peter Nash as he previews our highlights this EULAR, introducing some of the top abstracts we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.
T
The IMID Forum
1 PsA Podcast: Guselkumab & Secukinumab – All the Latest in Efficacy & Safety 26:47
26:47
Afspil senere
Afspil senere
Lister
Like
Liked
26:47Join Professors Peter Nash, Laura Coates, and Frank Behrens as they discuss the latest top research in PsA. The papers covered in this topical discussion highlight two fascinating therapeutics used in PsA treatment. This includes the latest evaluation of the efficacy and safety of guselkumab in DISCOVER-1 patients with active PsA by prior use of TNFi, as well as the latest investigation into the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.…
T
The IMID Forum
Dr Shikha Singla, Assistant Professor of Medicine at the Medical College of Wisconsin where she is also Medical Director of the psoriatic arthritis program. In this edition, Dr Singla discusses ehr latest paper 'Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.'…
T
The IMID Forum
1 AxSpA Podcast: AS Associated MACE & Upadacitinib's Long Term Safety 18:42
18:42
Afspil senere
Afspil senere
Lister
Like
Liked
18:42Join Dr. Sofia Ramiro and Professor Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses the incidence of MACEs in French patients newly benefiting from the French Long-term Illness scheme (LTI) for AS and to evaluate the effect of various treatments on the risk of MACE occurrence. Our second paper the goes on to evaluate the long-term safety profile for upadacitinib across RA, PsA, AS and AD.…
T
The IMID Forum
Join Prof Iain McInnes as he reviews two interesting papers that help to broaden our understanding and knowledge on the safety of biologic and targeted synthetic DMARDs. In the first of today’s papers, Matthew Baker and colleagues determine the risk of developing interstitial lung disease (ILD) in patients with RA, undergoing treatment with different biologic and targeted synthetic DMARDs. In the second paper, Lars Kristensen and team analyse data from ORAL Surveillance to help identify subpopulations with different relative risk (i.e., ’high-risk’ and ’low-risk’) with tofacitinib versus TNFi. To access detailed summary slides of the papers discussed today, visit cytokinesignalling.com.…
T
The IMID Forum
1 PsA Podcast: Herpes Zoster In JAK Inhibitor Therapies & The APEX Protocol 28:14
28:14
Afspil senere
Afspil senere
Lister
Like
Liked
28:14Join Professors Iain McInnes, Laura Coates, and Peter Nash as they discuss the latest top research in PsA. The first paper we will discuss aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with either TOFA, BARI or UPA. The second paper then goes on to describe the methodology being undertaken in the ground-breaking Phase 3b APEX study, which seeks to further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.…
T
The IMID Forum
Join Prof Iain McInnes as he reviews two interesting papers. In the first of today’s papers, Jeffrey Curtis and colleagues aimed to evaluate malignancies and their associations with baseline risk factors and CV risk scores with tofacitinib vs TNFi in a CV risk-enriched RA population from the ORAL Surveillance study. In the second paper today, Peter Taylor and his team analyse data from the baricitinib clinical trial programme for rheumatoid arthritis, atopic dermatitis, and alopecia areata, to help further characterise adverse events of special interest for JAK inhibitors in ‘at-risk’ populations.…
T
The IMID Forum
Dr. Charis Meng, a rheumatologist at the Hospital for Special Surgery and Assistant Professor at Weill Cornell Medical College in New York. In this edition, Dr Meng discusses her latest paper ‘Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis.’…
T
The IMID Forum
1 Discussing Rheumatology: February 2023 11:03
11:03
Afspil senere
Afspil senere
Lister
Like
Liked
11:03Join Prof Iain McInnes as he reviews two interesting papers. In the first paper, Professor Maxime Dougados and colleagues shed some more light into the findings from the ORAL Surveillance trial, in comparison to those seen in the tofacitinib clinical development programme. And, in the second paper, Professor Kevin Winthrop and colleagues continue to report on safety by providing us with the latest findings from their review into opportunistic infections associated with JAK inhibitor treatment for RA.…
T
The IMID Forum
Join Professors Atul Deodhar, Hideto Kameda, Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses new and emerging treatments for SpA. In particular it shines a light on treatments within axSpA. Following this, our second paper sought to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.…
T
The IMID Forum
1 Discussing Rheumatology: January 2023 13:18
13:18
Afspil senere
Afspil senere
Lister
Like
Liked
13:18Join Prof Iain McInnes as he reviews two interesting papers. In the first paper the authors cover aspects from mean disease activity scores after tapering to radiographic outcomes and safety, to help ascertain whether it is possible to withdraw MTX while maintaining disease control. The second paper then goes on to also analyse MTX withdrawal data, but this time to evaluate the performance of disease activity metrics. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com…
T
The IMID Forum
Professor Kevin Winthrop, Professor of Infectious Diseases, Public Health and Preventive Medicine, and Ophthalmology, from Oregon Health and Science University, USA, as well as a CSF Steering Committee member. In this edition Professor Winthrop discusses his recent paper 'Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.'…
T
The IMID Forum
Join Professor Philip Mease and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in December 2022. The first of our papers discusses the latest trial of a novel scoring system for inflammation and tissue damage, whilst the second paper compares adjunctive therapy usage in patients treated with IL-17A inhibitors.…
T
The IMID Forum
Dr Rebecca Haberman from the Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, USA. In this edition Dr Haberman disucsses her recent paper ‘Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.’…
T
The IMID Forum
Professor Roy Fleischmann, Clinical Professor of Medicine at the University of Texas Southwestern Medical Centre. In this addition Professor Fleischmann discusses his recent paper 'Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.'…
T
The IMID Forum
Dr Claudia Salinas, Director Pharmacoepidemiology at Eli Lilly and Company, Indianapolis, USA. In this addition Dr Salinas discusses her recent paper 'Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease registries and Claims Databases.'…
T
The IMID Forum
1 Discussing Rheumatology: December 2022 10:51
10:51
Afspil senere
Afspil senere
Lister
Like
Liked
10:51Join Prof Iain McInnes as he reviews two interesting papers. The first highlights one of the three systematic literature reviews carried out to inform the 2022 EULAR RA management recommendations task force with the available evidence published since 2019. The second paper in today’s podcast looks at the recommendations themselves, by Smolen, et al, and I’ll highlight what’s remained the same and what’s changed from the 2019 recommendations. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Join Professor Xenofon Baraliakos and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications details the 2022 ASAS-EULAR recommendations for the management of axial spondyloarthritis. The second of today’s papers explores the efficacy and safety of bDMARDs in axSpA managment. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Discussing Rheumatology: November 2022 10:24
10:24
Afspil senere
Afspil senere
Lister
Like
Liked
10:24Join Prof Iain McInnes as he reviews two interesting papers. The first paper aimed to compare the risk of MACEs and VTEs for patients initiating a JAKinib (tofacitinib and baricitinib) and those initiating adalimumab (TNFi) among a large and comprehensive real-world population of patients with RA. Our second paper aimed to evaluate the efficacy and safety of FIL200 and FIL100 compared with placebo and ADA, all with background MTX, in patients with MTX-IR RA in subgroups of those with all four PPFs versus those with fewer than four PPFs. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Join Professor Iain McInnes and Dr Frank Behrens as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at two key papers published in October 2022. Our first paper seeks to examine the efficacy and safety of ixekizumab in patients with PsA and PsO. Our second paper today will highlight the comparative efficacy of multiple treatments in PsA utilising new data within an NMA framework. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Discussing Rheumatology: October 2022 13:25
13:25
Afspil senere
Afspil senere
Lister
Like
Liked
13:25Discussing Rheumatology: October 2022 by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
Join Professors Iain McInnes and Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the feild of axSpA theraputics, providing their own insights and experience into two very interesting publications. The first of our publications reports the efficacy and safety results for patients treated with ixekizumab for up to 116 weeks. The second of today’s papers evaluated the effectiveness and safety profile of COMBIO, or Combination of Targeted Therapies, in clinical settings. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Discussing Rheumatology: September 2022 12:51
12:51
Afspil senere
Afspil senere
Lister
Like
Liked
12:51Join Prof Iain McInnes as he reviews two interesting papers. The first covers the impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis. The second discusses infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Dr Eduardo Mysler, from the School of Medicine, University of Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Mysler discusses his recent paper 'Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.'…
T
The IMID Forum
Join Professors Iain McInnes and Phillip Mease as well as Doctors Frank Behrens and Laura Coates as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in August 2022. Our first paper aims to highlight the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients by looking at a single tender point out of the six-point LEI. The second of today’s papers evaluates the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial. Finally, our third paper reports the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Dr Ameen Jubber, specialist registrar in rheumatology at the University Hospitals of Leicester NHS Trust, in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Jubber discusses his recent editorial paper reviewing the evidence for VTE risk in JAKinibs, and whether this risk also extends to the second-generation JAKinibs.…
T
The IMID Forum
Join Prof Iain McInnes as he reviews two interesting papers. The first covers new data from China on the first-in-human trial of KL130008. The second reports on the exposure-response analyses of filgotinib for dose confirmation. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Dr Kim Lauper, from the Division of Rheumatology, Department of Internal Medicine and Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneve, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Lauper discusses her latest paper; Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration.…
T
The IMID Forum
Join Prof. Baraliakos and Dr Mehta as they discuss the latest top research in axSpA. In this edition, our Steering Committee members look at three key papers published in July 2022. Our first paper investigated upadacitinib efficacy and safety in axSpA. The second of today’s looks at factors associated with drug-free remission in early onset axSpA patients. Finally, our third paper focuses on the association of bDMARD treatments with hospital acquired infections. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Join Prof Iain McInnes as he reviews two interesting papers from May and June. The first -by Faquetti , et al.- provides some insightful information into the pharmacological effects of tofacitinib and baricitinib. Our second paper then goes on to evaluate the real-life effectiveness and safety outcomes of four current second-line therapies of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Join Professors McInnes and Nash as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in May 2022. Our first paper highlights investigations of imaging characteristics and clinically assess heel enthesitis in SpA. The second of today’s paper evaluates the real-world effectiveness and persistence of the IL-12/23 inhibitor ustekinumab. Finally, our third paper reports the efficacy and safety of deucravacitinib in patients with active PsA. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Author Interview: Diego Kyburz by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
Discussing Rheumatology: June 2022 by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
Discussing axSpA: Episode 1 by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
Join Dr Laura Coates, Prof Enrique Soriano, Prof Chris Ritchlin, and Ass Prof Frank Behrens for our first podcast dedicated to the latest publications in PsA! In this edition, our Steering Committee members look at three key papers published in May 2022. The first, from Egeberg et al, looks at drug survival using a large, nationwide cohort study from the DANBIO and DERMBIO registries. The second looks at pooled data from SELECT-PsA-1 and -2 to investigate the safety profile of upadacitinib versus adalimumab in patients with active PsA and IR to biologic/non-biologic DMARDs. And finally, our speakers discuss new data from Merola et al on the effect of secukinumab CV risk factors and inflammatory biomarkers. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Douglas Veale takes you through our top picks from the selection of abstracts presented at the final day of EULAR 2022 (Saturday 4 June). Today's podcast covers RA, PsA, and axSpA.
T
The IMID Forum
Douglas Veale takes you through our top picks from the selection of abstracts at EULAR 2022 today (Friday 3 June). Today's podcast covers RA, PsA, and axSpA.
T
The IMID Forum
Laura Coates takes you through our top picks from the selection of abstracts at EULAR 2022 today (Thursday 2 June). Today's podcast covers RA, PsA, and axSpA.
T
The IMID Forum
1 DAY 1, RA: EULAR 2022 Daily Highlights 13:46
13:46
Afspil senere
Afspil senere
Lister
Like
Liked
13:46Laura Coates takes you through our top picks from the selection of rheumatoid arthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!…
T
The IMID Forum
1 DAY 1, PsA: EULAR 2022 Daily Highlights 12:32
12:32
Afspil senere
Afspil senere
Lister
Like
Liked
12:32Laura Coates takes you through our top picks from the selection of psoriatic arthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!…
T
The IMID Forum
1 DAY 1, axSpA: EULAR 2022 Daily Highlights 10:55
10:55
Afspil senere
Afspil senere
Lister
Like
Liked
10:55Laura Coates takes you through our top picks from the selection of axial spondyloarthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!…
T
The IMID Forum
EULAR 2022 Preview Podcast by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
Join Prof Iain McInnes as he reviews two interesting papers published in May 2022! The first – from Bartlett et al – looks at the impact of tofacitinib on fatigue, sleep and HRQoL in patients with RA. While the second assesses the impact of JAKi or abatacept on RA-interstitial lung disease. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Author Interview: Professor Peter Taylor 23:37
23:37
Afspil senere
Afspil senere
Lister
Like
Liked
23:37Professor Peter Taylor, from the University of Oxford in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Peter Taylor discusses pain control in early RA treated with baricitinib monotherapy.
T
The IMID Forum
1 Discussing Rheumatology: Pain, pneumonia and perspectives 13:47
13:47
Afspil senere
Afspil senere
Lister
Like
Liked
13:47Prof Iain McInnes reviews three papers this month!. The first – from Taylor et al – looks at pain control in early RA treated with baricitinib, the second investigates the immunogenicity of pneumococcal vaccination in patients with RA receiving upadacitinib and MTX, and the third paper is a perspective on regulatory changes in the wake of the ORAL SURVEILLANCE results. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Author Interview: Professor Rüdiger Müller 14:28
14:28
Afspil senere
Afspil senere
Lister
Like
Liked
14:28Professor Rüdiger Müller, Rheumazentrum Ostschweiz, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Rüdiger Müller discusses his paper on the impact of switching tofacitinib dose in patients with RA.
T
The IMID Forum
Discussing Rheumatology: March 2022 by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
1 Author Interview: Professor Roy Fleischmann 19:18
19:18
Afspil senere
Afspil senere
Lister
Like
Liked
19:18Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the long-term safety and efficacy of upadacitinib or adalimumab in patients with RA.…
T
The IMID Forum
1 Discussing Rheumatology: Tofacitinib safety and dose-switching in RA 7:31
7:31
Afspil senere
Afspil senere
Lister
Like
Liked
7:31Prof Iain McInnes reviews two papers this month, both on tofacitinib. The first looks at CV outcomes from the STAR-RA study, the second is a post-hoc analysis of ORAL Sequel looking into tofacitinib dose switching. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
ACR1540 Ana Rita Cruz - Machado by The Immune-Mediated Inflammatory Disease Forum
ACR1087 Omar Alsaed by The Immune-Mediated Inflammatory Disease Forum
T
The IMID Forum
1 ORAL Surveillance Author Interview – Roy Fleischmann 37:30
37:30
Afspil senere
Afspil senere
Lister
Like
Liked
37:30Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the ORAL Surveillance study into CV and cancer risks with tofacitinib in patients with RA.…
T
The IMID Forum
1 Author Author Interview: Professor Kevin Winthrop 17:49
17:49
Afspil senere
Afspil senere
Lister
Like
Liked
17:49Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the clinical management of HZ in patients with RA or PsA receiving tofacitinib.…
T
The IMID Forum
1 Discussing Rheumatology: HZ and ILD with tofacitinib in RA 6:20
6:20
Afspil senere
Afspil senere
Lister
Like
Liked
6:20Prof Iain McInnes reviews two papers this month, and discusses the risk of herpes zoster (HZ) events in patients with RA treated with tofacitinib, as well as interstitial lung disease (ILD), an extra-articular manifestation of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Discussing Rheumatology: Safety of filgotinib, and tofacitinib in pJIA 8:14
8:14
Afspil senere
Afspil senere
Lister
Like
Liked
8:14Prof Iain McInnes reviews two papers this month, and discusses exposure-adjusted incidence rates of TEAEs and AESIs with filgotinib, as well as the efficacy and safety of tofacitinib in pJIA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Author Interview: Professor Kevin Winthrop (December 2021) 22:13
22:13
Afspil senere
Afspil senere
Lister
Like
Liked
22:13Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the safety of filgotinib in patients with RA.
T
The IMID Forum
1 Author Interview: Professor Kevin Winthrop (November 2021) 20:31
20:31
Afspil senere
Afspil senere
Lister
Like
Liked
20:31Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the incidence and risk of herpes zoster in patients with RA receiving upadacitinib.…
T
The IMID Forum
1 Insights at ACR 2021: Basic Science / Beyond RA 40:11
40:11
Afspil senere
Afspil senere
Lister
Like
Liked
40:11Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
T
The IMID Forum
1 Insights at ACR 2021: PROs and JAK Treatment 48:07
48:07
Afspil senere
Afspil senere
Lister
Like
Liked
48:07Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
T
The IMID Forum
1 Insights at ACR 2021: Clinical Outcomes in RA 47:06
47:06
Afspil senere
Afspil senere
Lister
Like
Liked
47:06Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
T
The IMID Forum
1 Insights at ACR 2021: JAKs in Spondyloarthritis 30:06
30:06
Afspil senere
Afspil senere
Lister
Like
Liked
30:06Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
T
The IMID Forum
1 Insights at ACR 2021: COVID-19 Vaccination and Rituximab 31:49
31:49
Afspil senere
Afspil senere
Lister
Like
Liked
31:49Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
T
The IMID Forum
1 Insights at ACR 2021: Impact of COVID-19 on Practice 39:22
39:22
Afspil senere
Afspil senere
Lister
Like
Liked
39:22Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
T
The IMID Forum
1 Insights at ACR 2021: COVID Vaccinations 40:04
40:04
Afspil senere
Afspil senere
Lister
Like
Liked
40:04Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
T
The IMID Forum
1 Author Interview: Professor Atul Deodhar 24:20
24:20
Afspil senere
Afspil senere
Lister
Like
Liked
24:20Professor Atul Deodhar, professor of medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Atul Deodhar discusses his review on JAK-STAT signalling in spondyloarthritis and what that means for the use of JAK inhibitors for SpA treatment.…
T
The IMID Forum
1 Discussing Rheumatology: Risk of HZ with UPA, and JAKs in SpA 8:25
8:25
Afspil senere
Afspil senere
Lister
Like
Liked
8:25Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Author Interview: Professor Roy Fleischmann 28:54
28:54
Afspil senere
Afspil senere
Lister
Like
Liked
28:54Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the effect of baricitinib on inhibiting radiographic progression of structural joint damage over 5 years in patients with active RA.…
T
The IMID Forum
Grace Wright presents the Day 4 highlights of the key abstracts and posters presented at ACR 2021.
T
The IMID Forum
Professor Leonard Calabrese presents the Day 3 highlights of the key abstracts and posters presented at ACR 2021.
T
The IMID Forum
Grace Wright presents the Day 2 highlights of the key abstracts and posters presented at ACR 2021.
T
The IMID Forum
1 Discussing Rheumatology: Herpes Zoster and HBV 7:56
7:56
Afspil senere
Afspil senere
Lister
Like
Liked
7:56Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
Prof Calabrese presents the Day 1 highlights of the key abstracts and posters presented at ACR 2021.
T
The IMID Forum
A preview of the latest research at ACR 2021. Prof Ritchlin highlights important abstracts in cytokine signalling at the upcoming ACR Convergence.
T
The IMID Forum
1 Rheumatology Author Professor Paul Bird: Tofacitinib Effectiveness 19:38
19:38
Afspil senere
Afspil senere
Lister
Like
Liked
19:38Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.…
T
The IMID Forum
1 Discussing Rheumatology: Poor Prognostic Factors, Monotherapy, and Combination Therapy 8:12
8:12
Afspil senere
Afspil senere
Lister
Like
Liked
8:12Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Rheumatology Author Professor Kurt de Vlam: Pain Improvements 28:57
28:57
Afspil senere
Afspil senere
Lister
Like
Liked
28:57Kurt de Vlam, Professor of Rheumatology at UZ Leuven, Belgium. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor de Vlam assess the impact of baseline pain severity on pain response and the time to improvement in patients with PsA receiving tofacitinib.…
T
The IMID Forum
1 Rheumatology Author Professor Strand: Upadacitinib and PROs 25:15
25:15
Afspil senere
Afspil senere
Lister
Like
Liked
25:15Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology/Rheumatology, Biopharmaceutical Consultant at Stanford University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Strand discusses improvements in PROs in patients with RA treated with upadacitinib monotherapy.…
T
The IMID Forum
1 Discussing Rheumatology: Patient Reported Outcomes 12:03
12:03
Afspil senere
Afspil senere
Lister
Like
Liked
12:03Prof Iain McInnes discusses an essential part of the assessment of patients with rheumatic diseases; patient reported outcomes, or PROs. Improving PROs is crucial to effect tangible change in diseases and patient outcomes - to the extent that PROs are now included as an important component of many clinical trials. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Discussing Rheumatology: SELECT-PsA 2 and DMARDs in COVID-19 9:38
9:38
Afspil senere
Afspil senere
Lister
Like
Liked
9:38Prof Iain McInnes discusses long-term data from the SELECT-PsA 2 study, and the impact of DMARDs on COVID-19 outcomes. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Rheumatology Author Professor Mease: Upadacitinib 17:49
17:49
Afspil senere
Afspil senere
Lister
Like
Liked
17:49Philip Mease, Professor at the University of Washington School of Medicine in Seattle. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Mease discusses the longer-term safety and maintenance of efficacy of upadacitinib in patients with RA.…
T
The IMID Forum
1 Rheumatology Authors Jeffrey Sparks and Zachary Wallace 27:18
27:18
Afspil senere
Afspil senere
Lister
Like
Liked
27:18Jeffrey Sparks, from Brigham and Women's Hospital in Boston, and Zachary Wallace from the Massachusetts General Hospital. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Jeffery Sparks and Zachary Wallace discuss the latest results from the COVID-19 Global Rheumatology Alliance physician registry.…
T
The IMID Forum
1 Rheumatology Author Professor Francesco Ciccia: JAKis and Pain 19:27
19:27
Afspil senere
Afspil senere
Lister
Like
Liked
19:27Francesco Ciccia, Assistant Professor of Rheumatology at the University of Palermo in Italy. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Ciccia discusses with Professor Nash the impact of pain in patients with rheumatic diseases and the physiological basis of modulating nociceptive pain, speculating that JAK inhibitors may have a dual therapeutic role.…
T
The IMID Forum
1 Discussing Rheumatology: 2021 EULAR Highlights 15:42
15:42
Afspil senere
Afspil senere
Lister
Like
Liked
15:42Prof Iain McInnes discusses the main highlights of EULAR 2021 and the key takeaway messages. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Rheumatology Author Professor Stanley Cohen: Radiographic Progression 10:56
10:56
Afspil senere
Afspil senere
Lister
Like
Liked
10:56Stanley Cohen, Clinical Professor in the Department of Internal Medicine and Co-Director of the Division of Rheumatology from the UT Southwestern Medical Center and Presbyterian Hospital, Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Cohen discusses radiographic progression in patients with RA treated with tofacitinib.…
T
The IMID Forum
1 Insights at EULAR 2021: Day 4 Highlights 15:18
15:18
Afspil senere
Afspil senere
Lister
Like
Liked
15:18Dr Elena Nikiphorou presents the Day 4 highlights of the key abstracts and posters presented at EULAR 2021.
T
The IMID Forum
1 Insights at EULAR 2021: Day 3 Highlights 31:35
31:35
Afspil senere
Afspil senere
Lister
Like
Liked
31:35Professor Douglas Veale presents the Day 3 highlights of the key abstracts and posters presented at EULAR 2021.
T
The IMID Forum
1 Insights at EULAR 2021: Day 2 Highlights 18:34
18:34
Afspil senere
Afspil senere
Lister
Like
Liked
18:34Dr Elena Nikiphorou presents the Day 2 highlights of the key abstracts and posters presented at EULAR 2021.
T
The IMID Forum
1 Insights at EULAR 2021: Day 1 Highlights 24:31
24:31
Afspil senere
Afspil senere
Lister
Like
Liked
24:31Prof Veale presents the Day 1 highlights of the key abstracts and posters presented at EULAR 2021.
T
The IMID Forum
A preview of the latest research at EULAR 2021. Prof Edwards presents a preview of the upcoming EULAR 2021 congress, highlighting important abstracts and posters in cytokine signalling.
T
The IMID Forum
1 Discussing Rheumatology: PsA and Radiographic Progression 8:52
8:52
Afspil senere
Afspil senere
Lister
Like
Liked
8:52Prof Iain McInnes discusses upadacitinib in PsA, and radiographic progression with tofacitinib. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.…
T
The IMID Forum
1 Rheumatology Author Professor Yoshiya Tanaka: Filgotinib 29:24
29:24
Afspil senere
Afspil senere
Lister
Like
Liked
29:24Yoshiya Tanaka, Professor and Chairman of the department of Internal Medicine at the University of Occupational and Environmental Health in Kitakyushu, Japan. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tanaka discusses the safety and efficacy of filgotinib as a Novel JAK1-Preferential Inhibitor for the Treatment of RA.…
T
The IMID Forum
1 Rheumatology Author Dr Rishi Desai: VTE 32:14
32:14
Afspil senere
Afspil senere
Lister
Like
Liked
32:14Dr Rishi Desai, is an Assistant Professor of Medicine at Harvard Medical School and an Associate Epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Rishi Desai discusses Risk of venous thromboembolism associated with tofacitinib in patients with RA…
T
The IMID Forum
Prof Iain McInnes discusses JAKi and thromboembolism Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
T
The IMID Forum
1 Rheumatology Author Dr Ben Nowell: ArthritisPower 37:40
37:40
Afspil senere
Afspil senere
Lister
Like
Liked
37:40Dr Ben Nowell, Director of Patient-Centred Research at CreakyJoints, part of the Global Healthy Living Foundation. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Ben Nowell a real-world longitudinal study in ArthritisPower
T
The IMID Forum
Prof Iain McInnes discusses bone metabolism and PRO Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
T
The IMID Forum
1 Rheumatology Author Professor Paul Emery: Baricitinib 25:17
25:17
Afspil senere
Afspil senere
Lister
Like
Liked
25:17Professor Paul Emery, an arthritis Research UK Professor of Rheumatology, and Director of the Leeds Musculoskeletal Biomedical Research Centre at Leeds Teaching Hospitals Trust, UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Paul discusses how baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis…
T
The IMID Forum
1 Forum LIVE: Managing Patients During COVID 59:44
59:44
Afspil senere
Afspil senere
Lister
Like
Liked
59:44Professor Leonard Calabrese offers the latest advice on managing rheumatic patients during the pandemic and Professor Kimme Hyrich discusses the learnings from the COVID-19 Global Rheumatology Alliance registries, a year on from their inception.
T
The IMID Forum
1 Rheumatology Author Professor Lee Simon: Pain in RA 31:14
31:14
Afspil senere
Afspil senere
Lister
Like
Liked
31:14Dr Lee Simon, Principal Scientist in SDG LLG, Cambridge, US. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Lee Simon discusses pain in RA
T
The IMID Forum
1 Rheumatology Author Professor Tsutomu Takeuchi: Upadacitinib 20:30
20:30
Afspil senere
Afspil senere
Lister
Like
Liked
20:30Professor Tsutomu Takeuchi, HVice-President at Keio University and Professor of Medicine in the Division of Rheumatology and Clinical Immunology at Keio University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tsutomu Takeuchi discusses how upadacitinib monotherapy vs methotrexate monotherapy in methotrexate-naïve Japanese patients with RA…
T
The IMID Forum
1 Rheumatology Author Prof René Westhovens: Filgotinib 33:41
33:41
Afspil senere
Afspil senere
Lister
Like
Liked
33:41Professor René Westhovens, Emeritus Prof of Rheumatology at the KU Leuven Belgium and a >30 year track in clinical research in Rheumatoid Arthritis. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor René Westhovens discusses his latest paper on use of filgotinib in combination with methotrexate or as filgotinib monotherapy versus methotrexate monotherapy in patients with active RA.…
T
The IMID Forum
1 Discussing Rheumatology: February 2021 Podcast 11:47
11:47
Afspil senere
Afspil senere
Lister
Like
Liked
11:47Prof Iain McInnes discusses papers on filgotinib and the involvement of pain in RA. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
T
The IMID Forum
1 Perspectives in Inflammation - Dr Grace Wright 25:51
25:51
Afspil senere
Afspil senere
Lister
Like
Liked
25:51Founder and President of the Association of Women in Rheumatology. In this podcast Dr Grace C Wright discusses her careeer and the future of AWIR. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world-leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.…
Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.